[et_pb_section][et_pb_row][et_pb_column type=”4_4″][et_pb_text]
Lecanemab (Leqembi; Esai Co. Ltd. and Biogen) is an intravenously administered anti-amyloid beta (Aβ) protofibril antibody indicated for the treatment of Alzheimer disease.
If you have a Hayes login, click here to view the full report on the Knowledge Center.
[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section]